Payment overview · 2025
General Payments
$1,619.30
90 reported records · 19 companies
Healthcare provider profile · identity verified
Jasmine Bajaj, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BURLINGTON, NJ · NPI 1285992875
Verified facts
What the public records show
CMS Open Payments records show Jasmine Bajaj, MD received $1,619.30 in general payments during 2025 across 90 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $357.17 | 22.1% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $323.44 | 20.0% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $144.01 | 8.9% | 10 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $114.82 | 7.1% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $112.23 | 6.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.30 | 5.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.51 | 5.2% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $62.94 | 3.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.85 | 3.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $49.79 | 3.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.52 | 3.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.04 | 2.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.38 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.54 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.71 | 1.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.82 | 1.1% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.06 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.54 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.63 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,550.31 | 89 |
| Education | $68.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $193.10 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $176.06 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $168.34 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $168.34 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $155.10 | 9 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $114.82 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $100.27 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $100.27 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.47 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67.46 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $62.94 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.85 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $49.93 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.24 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.58 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $33.72 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.47 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.47 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $10.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 50 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 632 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 475 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 87 |
| Losartan Potassium | Losartan Potassium | 310 | 95 |
| Metformin Hcl | Metformin Hcl | 273 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 230 | 68 |
| Omeprazole | Omeprazole | 227 | 69 |
| Lisinopril | Lisinopril | 225 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 63 |
| Montelukast Sodium | Montelukast Sodium | 175 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 55 |
| Gabapentin | Gabapentin | 156 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 43 |
| Tramadol Hcl | Tramadol Hcl | 124 | 47 |
| Potassium Chloride | Potassium Chloride | 121 | 33 |
| Furosemide | Furosemide | 120 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 33 |
| Buspirone Hcl | Buspirone Hcl | 112 | 31 |
| Alprazolam | Alprazolam | 107 | 28 |
| Carvedilol | Carvedilol | 101 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 26 |
| Jardiance | Empagliflozin | 89 | 28 |
| Sertraline Hcl | Sertraline Hcl | 89 | 23 |
| Ozempic | Semaglutide | 87 | 19 |
| Simvastatin | Simvastatin | 77 | 24 |
| Famotidine | Famotidine | 74 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 23 |
| Meclizine Hcl | Meclizine Hcl | 71 | 17 |
| Ezetimibe | Ezetimibe | 69 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 29 |
| Meloxicam | Meloxicam | 65 | 25 |
| Mounjaro | Tirzepatide | 63 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 17 |
| Trazodone Hcl | Trazodone Hcl | 61 | 26 |
| Atenolol | Atenolol | 60 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 17 |
| Glimepiride | Glimepiride | 59 | 20 |
| Alendronate Sodium | Alendronate Sodium | 57 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 20 |
| Glipizide | Glipizide | 55 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 11 |
| Eliquis | Apixaban | 50 | 14 |
| Azithromycin | Azithromycin | 48 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 18 |
| Hydrocortisone | Hydrocortisone | 42 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Ibuprofen | Ibuprofen | 39 | 17 |
| Linzess | Linaclotide | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 36 | 11 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 34 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 11 |
| Naproxen | Naproxen | 29 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 13 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 26 |
| Mupirocin | Mupirocin | 26 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Prednisone | Prednisone | 24 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Gemtesa | Vibegron | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,619.30 · 90 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FASENRA, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, VOQUEZNA, VYNDAQEL, Veozah, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error